Market Intelligence, Preclinical Progress, and High-Purity Reagents for Epigenetic and Oncologic Development.
TarMart Solution Ecosystem & Related Targets
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SETD1A Full-Length / SET Domain Recombinant Protein. High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. Theoretical MW confirmed. E. coli/Insect expression optimized for enzymatic activity. | View SETD1A Products |
| Gene Delivery | SETD1A Premade ORF Lentivirus. Full-length ORF for stable cell line generation. CMV promoter, Puro selection. | View SETD1A Products |
| Benchmark Ab | Anti-SETD1A Recombinant Reference Antibody. Rabbit mAb sequence; ChIP/IP-grade positive control. | View SETD1A Products |
| Validator | SETD1A siRNA Set (3 unique sequences). For knockdown verification and specificity controls. | View SETD1A Products |
| Paralog Control | SETD1B Protein. Paralog specificity comparator. Critical for selectivity assays. | View SETD1B Products |
| Pathway Partner | KMT2A (MLL1) Protein. Redundant H3K4 methyltransferase. Cross-screening essential. | View KMT2A Products |
| COMPASS Scaffold | WDR5 Protein. Core component of COMPASS complex for PPI disruption studies. | View WDR5 Products |
| Epigenetic Counterpart | KDM5A (JARID1A) Protein. H3K4 demethylase; functional antagonist for pathway studies. | View KDM5A Products |
Critical Assay Challenges & The TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Paralog Selectivity (vs SETD1B, MLL1-4) | Homolog panel proteins (SETD1B, MLL1, MLL2, MLL3, MLL4) available with >95% purity; sequence-verified distinct epitopes. |
| COMPASS Complex Reconstitution | Full-length SETD1A co-expression systems with ASH2L/RBBP5/WDR5 available; sequence verified for structural fidelity. |
| Cellular Target Engagement | ChIP-grade reference antibodies and lentiviral overexpression system compatible with H3K4me3 detection assays. |
| Specificity Controls (False Positives) | Validated siRNA set (3 unique sequences) for knockdown confirmation; benchmark antibody for IP/WB validation. |
| Enzymatic Activity Validation | High-purity SET domain with confirmed SAM-binding capacity; theoretical MW match; no aggregates. |
Live SETD1A R&D Tracker
- ➤ View Active Clinical Trials
- ➤ Latest Resistance Research
- ➤ Latest Epigenetic Mechanism Research
- ➤ Recent Patent Filings
Global Clinical Landscape & Future Outlook
The race for SETD1A-targeted therapeutics is intensifying, driven by rare variant associations in schizophrenia and mixed oncologic phenotypes. As the field transitions from genetic validation to chemical probe development, major players are shifting focus from broad-spectrum epigenetic poisons to selective COMPASS complex modulators, including PROTACs and CNS-penetrant small molecules. Next-wave R&D targets synthetic lethality in oncology (e.g., combining SETD1A inhibition with PARP/DDR inhibitors) and gain-of-function restoration for neurodevelopmental disorders like schizophrenia. Paralog selectivity (vs SETD1B and MLL family) remains the foremost druggability challenge, necessitating high-purity recombinant proteins and robust biochemical assays.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor | Academic Consortia, Early-stage Biotech | Schizophrenia (haploinsufficiency model), AML, MYC-driven solid tumors | Enzymatic activity assay with high-purity SET domain and full paralog selectivity panel |
| PROTAC Degrader | Undisclosed Preclinical Innovators | Refractory cancers (gain-of-function contexts) | Ternary complex validation using high-purity full-length SETD1A and E3 ligase proteins |
| Genetic Modulator (CRISPR/ASO) | Neurology-focused Biopharmas | Schizophrenia (expression restoration) | Expression validation via lentiviral overexpression and specific siRNA controls |
| PPI Disruptor / Molecular Glue | Pharma-Academic Partnerships | Tumors with H3K4 hypermethylation | Reconstituted COMPASS subcomplex (SETD1A-ASH2L-WDR5) for TR-FRET/AlphaScreen |
Functional Domains & Key Mutations
SETD1A contains three functional domains (RRM, SET, Post-SET) confirmed by UniProt. Clinically relevant mutations include NEDSID-associated variants (VAR_085029, VAR_085030) and an EPEO2 mutation (VAR_083962) that affects synapse development in mouse models. These mutations underscore the need for custom recombinant proteins and mutation-specific assay tools—capabilities available through TarMart's sequence-verified product line.